Dr. Kyriakopoulos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-745-3399- Is this information wrong?
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 2007 - 2010
Aristotle University of Thessaloniki School of MedicineClass of 2003
Certifications & Licensure
WI State Medical License 2014 - 2025
FL State Medical License Active through 2014
OH State Medical License 2013 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer Start of enrollment: 2018 Jan 17
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Start of enrollment: 2018 Apr 26
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Start of enrollment: 2022 Aug 17
Roles: Principal Investigator
Publications & Presentations
PubMed
- A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with ad...Kathryn E Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E Kyriakopoulos, Randy F Sweis, Marc Chamberlain, Brian I Rini> ;Investigational New Drugs. 2024 Apr 1
- 1 citationsThe effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine EC...Walter, A., Lee, J., Streck, J., Gareen, I., Herman, B., Kircher, S., Carlos, R., Kumar, S., Mayer, I., Saba, N., Fenske, T., Neal, J., Atkins, M., Hodi, F., Kyriakopo...> ;Cancer. 2024 Feb 1
- Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2024 Jan 19
- Join now to see all
Journal Articles
- Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal TherapyVadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate
Lectures
- A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Interlesional response assessment with F-sodium fluoride (F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) tre...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Press Mentions
ERS: Anti-IL-6 Receptor mAb Reduces Covid-19 MortalitySeptember 9th, 2021
Carbone Experts Present Latest Research at World's Largest Cancer MeetingMay 31st, 2019- Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018
- Join now to see all
Hospital Affiliations
- Aspirus Divine Savior Hospital & ClinicsPortage, Wisconsin
University HospitalMadison, Wisconsin
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
